The anti-mycobacterial activity of a diterpenoid-like molecule operates through nitrogen and amino acid starvation
Crusco, Alessandra; Alves Baptista, Rafael; Bhowmick, Sumana; Beckmann, Manfred; Mur, Luis; Westwell, Andrew D.; Hoffmann, Karl

Published in:
Frontiers in Microbiology
DOI:
10.3389/fmicb.2019.01444
Publication date:
2019
Citation for published version (APA):
The Anti-mycobacterial Activity of a Diterpenoid-Like Molecule Operates Through Nitrogen and Amino Acid Starvation

Alessandra Crusco1,2, Rafael Baptista1, Sumana Bhowmick1, Manfred Beckmann1, Luis A. J. Mur1, Andrew D. Westwell2 and Karl F. Hoffmann1*

1 Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, United Kingdom, 2 School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom

A library of 14 minimally cytotoxic diterpenoid-like compounds (CC50 > 70 µM on HepG2 human liver cells) was screened against *Mycobacterium smegmatis*, *Staphylococcus aureus*, and *Escherichia coli* to determine antimicrobial activity. Some compounds with a phenethyl alcohol (PE) core substituted with a β-cyclocitrinal derivative demonstrated anti-mycobacterial activity, with the most active being compound 1 (MIC = 23.4 mg/L, IC50 = 0.6 mg/L). Lower activity was exhibited against *S. aureus*, while no activity was displayed against *E. coli*. Low cytotoxicity was reconfirmed on HepG2 cells and additionally on RAW 264.7 murine macrophages (SI for both cell lines > 38). The sub-lethal (IC50 at 6 h) effect of compound 1 on *M. smegmatis* was examined through untargeted metabolomics and compared to untreated bacteria and bacteria treated with sub-lethal (IC50 at 6 h) concentrations of the antituberculosis drugs ethambutol, isoniazid, kanamycin, and streptomycin. The study revealed that compound 1 acts differently from the reference antibiotics and that it significantly affects amino acid, nitrogen, nucleotides and folate-dependent one-carbon metabolism of *M. smegmatis*, giving some insights about the mode of action of this molecule. A future medicinal chemistry optimization of this new anti-mycobacterial core could lead to more potent molecules.

Keywords: terpenoids, diterpenoids, mycobacteria, tuberculosis, *Mycobacterium smegmatis*, untargeted metabolomics

INTRODUCTION

Tuberculosis (TB), a highly infectious disease caused by the *Mycobacterium tuberculosis* (MTB), is included amongst the top 10 causes of human mortality according to the World Health Organization (World Health Organization [WHO], 2018). The first anti-TB agent to be discovered was streptomycin, but MTB resistance to this drug quickly evolved (Lienhardt et al., 2012). Current treatment for TB includes a 6-month combination therapy including the first-line drugs rifampicin, isoniazid, pyrazinamide and ethambutol (Lienhardt et al., 2012). However, multidrug-resistant TB (MDR-TB) has also developed, requiring affected patients to subsequently undergo 20 months of...
chemotherapy with more toxic second-line drugs; these regimes are associated with lower treatment success as well as emergence of additional resistance to certain second line drugs (kanamycin and fluoroquinolones) and the evolution of extensive drug resistant (XDR) TB (Mwanzia et al., 2015). As patients affected by MRD-TB and XDR-TB have low chances of survival, the discovery of new anti-TB drugs is an urgent priority.

In this study, a library of minimally cytotoxic diterpenoid-like compounds (CC50 > 70 μM on HepG2 human liver cells), previously synthesized and tested for anthelmintic activity (Crusco et al., 2018), was screened against *Mycobacterium smegmatis*. *M. smegmatis* is a non-pathogenic and fast-growing *Mycobacterium* that demonstrates drug-response characteristics comparable to the highly infectious MDR-TB and, for these characteristics, represents a suitable model for anti-MTB drug discovery (Chaturvedi et al., 2007). In particular, some compounds containing a phenethyl alcohol (PE) core substituted with a β-cyclocitril (cyclohexenyl) derivative showed anti-mycobacterial activity, with the most active being compound 1 (MIC = 23.4 mg/L, IC50 = 0.6 mg/L). Compounds were also screened against representative Gram positive (*Staphylococcus aureus*) and Gram negative (*Escherichia coli*) bacteria to ascertain generic antimicrobial properties. In contrast to *M. smegmatis*, low to no activity was found for *S. aureus* and *E. coli* suggesting some degree of diterpenoid selectivity. As PE is a known antimicrobial (Corre et al., 1990; Lucchini et al., 1990), the anti-mycobacterial activity of this compound was additionally tested. Here, the MIC was found to be > 125 mg/L suggesting that the β-cyclocitril derivative substituent and/or the 4-methoxy aromatic substituent are essential for the anti-mycobacterial activity.

Metabolomics-based investigations of compound 1’s anti-mycobacterial activity indicated modulation of amino acid, nitrogen, nucleotides, and folate-dependent one-carbon metabolism within the bacteria that was not observed with other tested established antibiotics. In particular, a condition of nitrogen/amino acid starvation was identified, which could be at the base of compound 1’s mode of action.

In conclusion, we found a selective anti-mycobacterial core that, to the best of our knowledge, has not been explored yet and whose optimization could bring to the development of more potent anti-mycobacterial compounds. The mechanism of action of this class of molecules has been investigated by untargeted metabolomics revealing a significant decrease in nitrogen-containing metabolites and a possible nitrogen/amino acid starvation effect. Further studies will be necessary to confirm the generated hypothesis and to give new insights on this family of molecules.

**MATERIALS AND METHODS**

**Chemicals**

The diterpenoid library was synthesized as described previously (Crusco et al., 2018). Chiral compounds 1, 3, 6, 8, 10, 11, 12, 13, and 14 were synthesized and tested as racemic mixtures (Crusco et al., 2018). After initial screening (see paragraph below), compound 1 was resynthesized and retested to confirm the antimicrobial activity. Streptomycin sulfate, ethambutol dihydrochloride, isoniazid and phenetyl alcohol were obtained from Sigma. Kanamycin sulfate was obtained from Gibco. All compounds, the synthetic diterpenoids and the standard anti-TB drugs, were solubilized as stock solutions of 2.5 mg/mL in (1:1) methanol/water.

**Bacterial Growth, Minimum Inhibitory Concentration (MIC) Calculation, and IC50 Determination**

All procedures were performed in a biosafety level 2 (BSL2) cabinet. *S. aureus* ATCC 29213 and *E. coli* ATCC 25922 were cultured in Luria-Bertani (LB) medium at 37°C with aeration at 200 rpm for 24 h, while *M. smegmatis* mc²155 was cultured in LB medium supplemented with 0.2% (v/v) glycerol and 0.05% (v/v) Tween 80 at 37°C with aeration at 200 rpm for 48 h. The stationary phase cultures were then used for minimum inhibitory concentration (MIC) determination using the broth microdilution method, in fresh LB medium, in a 96-well plate (European Committee for Antimicrobial Susceptibility Testing [EUCAST] of the European Society of Clinical Microbiology and Infectious Diseases [ESCMID], 2003). All compounds were tested in triplicate using an initial bacterial concentration of 5.0 × 10⁵ colony forming units (CFU)/mL at final concentrations of 250 mg/L and 125 mg/L (5% and 2.5% v/v methanol). Compounds with no visible growth at 125 mg/L were further evaluated with progressing dilutions. The MIC was determined as the lowest concentration of a compound at which no growth was visible after 24 h (S. aureus and E. coli) or after 48 h (M. smegmatis). For compound 1, dilutions were repeated in three independent experiments where the optical density (OD₆₀₀) was measured in a Hidex plate spectrophotometer and absorbance data were used for the calculation of an IC₅₀ value. The IC₅₀ value represents a compound concentration that inhibits 50% of bacterial growth (negative control as 100%) and was obtained from a dose response titration (250–0.09 mg/L). Dose response curves were obtained by non-linear regression, after log transformation of concentrations and data normalization using GraphPad Prism 7.02.

**Mammalian Cell Culture and MTT Assay**

HepG2 human liver cancer cells were grown in BME culture media with the addition of 10% v/v Fetal Bovine Serum, 1% v/v MEM non-essential amino acid solution, 1% v/v 200 mM L-Glutamine, 1% v/v antibiotic/anti-mycotic. RAW 264.7 murine macrophage cells were grown in DMEM media with the addition of 10% v/v Fetal Bovine Serum, 1% v/v 200 mM L-Glutamine, 1% v/v antibiotic/anti-mycotic. When ~80% confluency was reached, all cells were prepared for MTT viability assays as previously described (Nur-e-alam et al., 2017; Crusco et al., 2018). Briefly, 2.5 × 10⁴ cells per well were cultured in a black walled 96-well microtiter plate (Fisher Scientific, Loughborough, United Kingdom) and incubated for 24 h at 37°C in a humidified atmosphere with 5% CO₂. Test compounds were then titrated from 100 to 3.13 μM (1.25 final % DMSO) and negative (DMSO: 1.25%) and positive (1% v/v Triton X-100) (Dayeh et al., 2004)
<table>
<thead>
<tr>
<th>Compounds</th>
<th>Structures</th>
<th>RB</th>
<th>HBA</th>
<th>HBD</th>
<th>cLogP</th>
<th>MW</th>
<th>LRV</th>
<th>S. aureus</th>
<th>E. coli</th>
<th>M. smeg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><img src="image1.png" alt="Structure" /></td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>3.90</td>
<td>274.40</td>
<td>0</td>
<td>62.5</td>
<td>&gt;250</td>
<td>23.4</td>
</tr>
<tr>
<td>2</td>
<td><img src="image2.png" alt="Structure" /></td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>4.01</td>
<td>272.38</td>
<td>0</td>
<td>&gt;250</td>
<td>&gt;250</td>
<td>62.5</td>
</tr>
<tr>
<td>3</td>
<td><img src="image3.png" alt="Structure" /></td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>3.88</td>
<td>274.40</td>
<td>0</td>
<td>250</td>
<td>&gt;250</td>
<td>31.25</td>
</tr>
<tr>
<td>4</td>
<td><img src="image4.png" alt="Structure" /></td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>4.01</td>
<td>272.38</td>
<td>0</td>
<td>250</td>
<td>&gt;250</td>
<td>125</td>
</tr>
<tr>
<td>5</td>
<td><img src="image5.png" alt="Structure" /></td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>4.98</td>
<td>284.44</td>
<td>0</td>
<td>&gt;250</td>
<td>&gt;250</td>
<td>250</td>
</tr>
<tr>
<td>6</td>
<td><img src="image6.png" alt="Structure" /></td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>5.12</td>
<td>300.48</td>
<td>1</td>
<td>250</td>
<td>&gt;250</td>
<td>250</td>
</tr>
<tr>
<td>7</td>
<td><img src="image7.png" alt="Structure" /></td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>5.24</td>
<td>298.46</td>
<td>1</td>
<td>62.5</td>
<td>&gt;250</td>
<td>250</td>
</tr>
<tr>
<td>8</td>
<td><img src="image8.png" alt="Structure" /></td>
<td>6</td>
<td>4</td>
<td>1</td>
<td>3.76</td>
<td>334.45</td>
<td>0</td>
<td>&gt;250</td>
<td>&gt;250</td>
<td>&gt;250</td>
</tr>
<tr>
<td>9</td>
<td><img src="image9.png" alt="Structure" /></td>
<td>6</td>
<td>4</td>
<td>0</td>
<td>3.95</td>
<td>332.43</td>
<td>0</td>
<td>&gt;250</td>
<td>&gt;250</td>
<td>&gt;250</td>
</tr>
<tr>
<td>10</td>
<td><img src="image10.png" alt="Structure" /></td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>3.42</td>
<td>256.34</td>
<td>0</td>
<td>&gt;250</td>
<td>&gt;250</td>
<td>&gt;250</td>
</tr>
<tr>
<td>11</td>
<td><img src="image11.png" alt="Structure" /></td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>3.42</td>
<td>286.37</td>
<td>0</td>
<td>&gt;250</td>
<td>&gt;250</td>
<td>&gt;250</td>
</tr>
<tr>
<td>12</td>
<td><img src="image12.png" alt="Structure" /></td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>4.06</td>
<td>272.38</td>
<td>0</td>
<td>&gt;250</td>
<td>&gt;250</td>
<td>125</td>
</tr>
<tr>
<td>13</td>
<td><img src="image13.png" alt="Structure" /></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>4.69</td>
<td>258.40</td>
<td>0</td>
<td>250</td>
<td>&gt;250</td>
<td>62.5</td>
</tr>
<tr>
<td>14</td>
<td><img src="image14.png" alt="Structure" /></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>4.70</td>
<td>258.40</td>
<td>0</td>
<td>&gt;250</td>
<td>&gt;250</td>
<td>&gt;250</td>
</tr>
<tr>
<td>PE</td>
<td><img src="image15.png" alt="Structure" /></td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1.64</td>
<td>122.16</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
<td>250</td>
</tr>
</tbody>
</table>

Chemical structures and physicochemical properties of compound library calculated by SwissADME (Daina et al., 2017). RB, number of rotatable bonds; HBA, number of H-bond acceptors; HBD, number of H-bond donors; cLogP, consensus Log P; MW, molecular weight; and LRV, Lipinski’s rule violations. For predicted good oral bioavailability, values should be <10, <10, ≤5, ≤500, and ≤1, respectively. Minimum inhibitory concentration (MIC; mg/L) of compound library against Staphylococcus aureus, Escherichia coli and Mycobacterium smegmatis. Values of >250 are considered to indicate no significant antimicrobial activity.
FIGURE 1 | Principal component analysis (PCA) of treated M. smegmatis metabolome. PCA score plots (n = 6 and 95% confidence interval illustrated, clear outliers removed) of normalized m/z intensities of metabolites extracted from M. smegmatis treated with compound 1 (1) compared to control bacteria (C) and to bacteria treated with ethambutol (E), isoniazid (I), kanamycin (K), and streptomycin (S) for 6 h. Plots indicate metabolome differences between treatment groups based on metabolite features detected by FIE-HRMS in (A) positive and (B) negative ionization mode. Antibiotics with similar mechanism of action were grouped into those with activity on cell wall (ethambutol and isoniazid, CW) and on protein synthesis (kanamycin and streptomycin, PS) for both (C) positive and (D) negative mode. Compound 1 did not show any overlap with these antibiotics.
controls included. After a 24 h incubation, the MTT assay was performed as described (Nur-e-alam et al., 2017; Crusco et al., 2018) and an IC$_{50}$ value calculated from absorbance data as described in the previous paragraph.

**Metabolomics Sample Preparation and Metabolite Extraction**

The procedure previously described by Baptista et al. (2018) was followed with minor modifications. Briefly, a total of 1.5 L of mycobacterial culture was incubated and grown in constant shaking at 200 rpm at 37°C. After 48 h, at OD$_{600}$ = 0.6, thirty-six samples (6 biological replicates × 6 treatments; compound 1, ethambutol, isoniazid, kanamycin, streptomycin and media only control) of 30 mL bacterial culture (10 mL × each time point; 0, 3, and 6 h) were dosed with compound 1 and antibiotics, at the concentration able to inhibit 50% of growth at OD$_{600}$ = 0.6 after 6 h (31.25 mg/L for compound 1, ethambutol and isoniazid, 7.3 mg/L for kanamycin, and streptomycin). At each time point, an aliquot of 10 mL culture was harvested from each sample, immersed in liquid nitrogen to quench bacterial metabolism and stored at -80°C. In preparation for the extraction, samples were thawed, centrifuged (10,000 rpm), washed with 0.85% NaCl and adjusted to an OD$_{600}$ of 2. Extraction was performed by four freeze-thaw cycles and vortexing in 200 µL of a chloroform/methanol/water 1:3:1 solution. After a final centrifugation, 100 µL of solution were transferred in mass vials for flow infusion electrospray high-resolution mass spectrometry (FIE-HRMS) fingerprinting analysis.

**Metabolomics Analysis**

FIE-HRMS was performed in the High Resolution Metabolomics Laboratory (HRML) at Aberystwyth University. A Q-Exactive Plus mass analyzer equipped with an UltiMate 3000 UHPLC system (Thermo Fisher Scientific) generated metabolite fingerprints in positive-negative polarity switching mode. Ion intensities were acquired between 50 and 1200 m/z for flow infusion electrospray high-resolution mass spectrometry (FIE-HRMS) fingerprinting analysis. MetaboAnalyst 4.0. – Statistical analysis (Chong et al., 2018) was used to perform principal component (PCA). MetaboAnalyst 4.0 – MS peaks to pathway (Chong et al., 2018) was used to identify metabolites (tolerance = 3 ppm) and significant affected metabolic pathways (model organism = S. aureus). MetaboAnalyst pathway identification is based on mummichog, an algorithm able to predict biological activity directly from mass spectrometry data, avoiding the a priori identification of metabolites (Li et al., 2013). Mummichog plots all possible matches in the metabolic network and then looks for local enrichment, providing reproduction of true activity, as the false matches will distribute randomly (Li et al., 2013). Examples of key-metabolites in local enrichment were analyzed for significant difference (t-test) between control and treatment on Microsoft Excel and by GraphPad Prism 7.02.

**RESULTS AND DISCUSSION**

To investigate potential antimicrobial activities of the previously synthesized diterpenoids (Crusco et al., 2018), a total of 14 related compounds were compared for their physicochemical properties and screened against S. aureus, E. coli and M. smegmatis (Table 1). All the compounds showed a predicted good oral bioavailability and drug-likeness, according to property predictions performed by SwissADME (Daina et al., 2017). The most potent antimicrobial activity was found for compound 1 with a MIC of 23.4 mg/L on M. smegmatis, 62.5 mg/L on S. aureus and no activity on E. coli even at the highest concentration tested (250 mg/L). When compound 1 was compared to the other screened analogs, some trends in structure-activity relationship (SAR) were identified. Replacement of the alcoholic function (C-OH) with the corresponding oxidized keto form (C = O) considerably decreased the anti-mycobacterial activity (e.g., 1 vs. 2 and 3 vs. 4), while the presence of the 4-methoxy substituent (-OCH$_3$) on the phenyl ring was responsible for increased activity (e.g., 1 vs. 3, 6, 8; 2 vs. 4; 13 vs. 14). As the molecules (1 and 3) sharing the alcoholic functions are structural analogs of PE, a known antimicrobial (Corre et al., 1990; Lucchini et al., 1990), this compound was also tested on M. smegmatis. However, PE was only active at the top concentration tested (250 mg/L), suggesting that the cyclo-hexenyl substituent and/or the 4-methoxy aromatic component of compounds 1 and 3 are the critical features associated with the anti-mycobacterial effects. The role of these substituents in the enhancement of the anti-mycobacterial activity is currently unknown, but may be linked to increased hydrophobic interactions of the molecule with a hypothetical target protein contained within M. smegmatis.

**Table 2** Anti-mycobacterial and cytotoxic activity of compound 1.

<table>
<thead>
<tr>
<th>Compound</th>
<th>MIC$^a$</th>
<th>Viability of HepG2 cells at MIC$^b$ (%)</th>
<th>Viability of RAW cells at MIC$^b$ (%)</th>
<th>IC$_{50}^c$</th>
<th>CC$_{50}$ on HepG2 cells$^d$</th>
<th>CC$_{50}$ on RAW cells$^d$</th>
<th>Selectivity Index$^d$</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>23.4 [85.3]</td>
<td>104 ± 0.14</td>
<td>88 ± 0.29</td>
<td>0.6 (0.2-1.3) [2.2 (0.8-4.8)]</td>
<td>&gt;27.4 [&gt;-100]</td>
<td>&gt;27.4 [&gt;-100]</td>
<td>&gt;38.5</td>
</tr>
</tbody>
</table>

$^a$Values expressed as mg/L [µM] and confirmed in triplicate. $^b$Values expressed as average percentage ± SD of three replicates. $^c$IC$_{50}$ determined from three independent experiments and expressed as mg/L [µM] with 95% confidence interval. $^d$Calculated from IC$_{50}$ on M. smegmatis when compared to the CC$_{50}$ on mammalian cells.
As compound 1 demonstrated the best antimicrobial activity (M. smegmatis > S. aureus > E. coli), it was resynthesized (Crusco et al., 2018) and used in re-confirmatory experiments. Here, the anti-mycobacterial activity and the low HepG2 human liver cell cytotoxicity were confirmed (Table 2). Furthermore, as MTB predominantly resides in alveolar macrophages (Dheda et al., 2016), compound 1's effect on RAW 264.7 murine macrophages was also determined (Table 2). Similar to findings in HepG2 cells, compound 1 exhibited low overt macrophage cytotoxicity (CC50 > 100 µM) and, consequently, high anti-mycobacterial selectivity (Table 2).

The activity of compound 1 was further investigated by examining metabolomic changes following its addition to M. smegmatis cultures (at its IC50 value at 6 h, 31.25 mg/L) for 6 h using methodologies previously described by Baptista et al. (2018) and further assessed in MetaboAnalyst 4.0 (Chong et al., 2018). Extracted metabolites derived from treated vs control M. smegmatis were profiled by using FIE-HRMS, a cutting edge high-throughput method used toward mode of action studies within bacteria. Unsupervised principal component analysis (PCA) of the identified m/z features indicated that the metabolome of bacteria treated with compound 1 was quite distinct from the metabolome of bacteria treated with ethambutol, isoniazid, kanamycin, and streptomycin (each also at IC50 values) as well as untreated bacteria (Figures 1A,B). Treatment of M. smegmatis with antibiotics having similar mechanisms of action (cell wall disruption by inhibition of mycolic acid synthesis for ethambutol and isoniazid (Chakraborty and Rhee, 2015); protein synthesis inhibition through binding to the 30 s subunit of ribosomes for streptomycin and kanamycin (Poulilakos and Falagas, 2013) showed overlapping metabolomics signatures. Accordingly, these signatures group further into two clusters, and sample profiles derived from those antibiotics acting on M. smegmatis cell wall components clustered away from those affecting protein synthesis (Figures 1C,D). Bacteria treated with compound 1 did not show any overlapping metabolomics signature with either the control bacteria or four antibiotic-treated bacteria, suggesting a different mechanism of action.

To identify the metabolites responsible for separating control-and compound 1- treated M. smegmatis samples in PCA (at 6 h), the metabolome data of these two samples was analyzed using MetaboAnalyst 4.0 (Chong et al., 2018). A total of 1902 m/z features were differentially found between the two samples in the positive ionization mode, whereas 1456 m/z HRMS elements were differently present amongst the two samples in the negative ionization mode (p < 0.001). Examination on these signatures by MetaboAnalyst 4.0 – MS peaks to pathway revealed that amino acid-, nitrogen-, nucleotide- and folate-dependent one-carbon metabolism are the most significantly affected pathways in M. smegmatis samples treated with compound 1 (Table 3 for significant different pathways, Supplementary Information for all identified metabolites and pathways, Supplementary Tables S1–S4).

Upon further interrogation of the statistically significant metabolites (Figure 2), most amino acids identified were less abundant in compound 1 treated M. smegmatis samples when compared to the controls, as well as metabolites belonging to nitrogen metabolism and the urea cycle (carbamoyl phosphate, citrulline, ornithine, glutamate-5-semialdehyde) (Figures 2A,B). This trend was not observed in the reference antibiotics treatments (Supplementary Figure S1). Significantly affected pathways also included pyrimidine metabolism and, on the limit of significance (p = 0.06), purine metabolism. In particular, most nucleosides (adenosine, guanosine, cytidine, uridine, thymidine and their mono and di-phosphate forms) were significantly less abundant, while some nucleoside metabolic products (xanthine, xanthosine monophosphate, adenine, phosphoribosyl pyrophosphate) were found to be more abundant in compound 1 treated M. smegmatis samples compared to controls (Figure 2B and Supplementary Figure S2A).
FIGURE 2 | Mycobacterium smegmatis metabolic networks affected by compound 1. (A) Compound 1 significantly affects amino acid and nitrogen metabolisms. All the significantly more abundant metabolites are colored in red, while the less abundant metabolites in green (when compared to the control M. smegmatis samples). Identified hits with no significant changes are in orange. Corresponding names for each metabolite and pathway are also annotated. For pyrimidine, purine and folate-dependent one-carbon metabolic networks see Supplementary Figure S2. (B) Some key metabolites with significantly (*p < 0.01, **p < 0.001) different concentrations between control and treatment are indicated.
Collectively, the metabolomics data could suggest that compound 1, and its related analogs, induces nitrogen and/or amino acid starvation. This would also impact on purine and pyrimidine synthesis through their dependence on glutamine and glutamate. Therefore, the lower concentrations of nucleosides and the increased concentration of a nucleoside precursor (phosphoribosyl pyrophosphate) could suggest a downregulation of nucleoside biosynthesis. Equally, this data could suggest that increased catabolism is found in compound 1 treated *M. smegmatis* as more degradation metabolites including xanthine, xanthosine monophosphate and adenine are all present when compared to controls. These findings are in agreement with previous reported studies which demonstrated, at the transcriptome level, a downregulation of nucleoside biosynthesis, and an upregulation of nucleotide catabolism in nitrogen-starving mycobacteria (Jeflberger et al., 2013; Petridis et al., 2015). In addition, as folate-dependent one-carbon metabolism is essential for nucleotide synthesis, our results (Figure 2B and Supplementary Figure S2B) fit well to a nitrogen-limited intake hypothesis. This hypothesis is also supported by the significant decreased concentration of glutamine when compared to 2-oxo-glutarate (no significant difference) in compound 1 treated samples (Figure 2B), as the ratio of glutamine/2-oxo-glutarate is a main sensor of decreased nitrogen levels in mycobacteria (Gouzy et al., 2014).

Although it is currently not clear how compound 1 causes the observed nitrogen/ amino acid starvation, some mechanisms are hypothetically possible. For example, by interacting with cell membranes (diterpenoids are widely reported to interact with eukaryotic and prokaryotic cell membranes) (Tsuchiya, 2015), compound 1 could interfere with ammonium, and/or amino acid transporters, thereby, decreasing nitrogen intake from external sources. In support of this hypothesis, terpenoids interfering with amino acid transport have been previously described in eukaryotic cells (Wu et al., 2007; Wang et al., 2014; Wibowo et al., 2018). Whether this can also occur in prokaryotes is currently unknown, but our metabolomic data suggests it is a possibility. Alternatively, compound 1 may alter one of the internal enzymatic systems responsible for nitrogen utilization in mycobacteria (Gouzy et al., 2014; Petridis et al., 2015) and, thus, interferes with amino acids synthesis. This could indirectly cause the overconsumption of available amino acids and nitrogen-based compounds by alteration of different pathways. The consequences of nitrogen-limited conditions would negatively affect protein synthesis (in a different way from kanamycin and streptomycin, which bind the 30 s subunit of prokaryotic ribosomes) (Poulakakos and Falagas, 2013) as well as both DNA and RNA synthesis ultimately leading to bacteria death. However, further analyses at the molecular level are necessary to give new indications about the mechanism of action and to eventually confirm the proposed hypotheses.

In conclusion, a selective anti-mycobacterial core that may act through direct or indirect alteration of nitrogen/amino acids metabolism of the mycobacteria was identified. Further structural modifications of this core could lead to an optimization of its potency and to the development of new anti-mycobacterial molecules.

**DATA AVAILABILITY**

All datasets generated for this study are included in the manuscript and/or the Supplementary Files.

**AUTHOR CONTRIBUTIONS**

AC and KH conceived and designed the experiments. AC conducted the experiments (compound synthesis and characterization). AC and SB contributed to the bacterial screening. AC, RB, MB, and LM contributed to the bacterial screening (metabolomics). AC prepared the original draft of the manuscript. All authors edited and revised the manuscript.

**FUNDING**

We thank the Welsh Government, Life Sciences Research Network Wales scheme for financial support to AC and RB. IBERS receives strategic funding from the BBSRC.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2019.01444/full#supplementary-material

**FIGURE S1** *Mycobacterium smegmatis* metabolic networks after reference antibiotics treatments. Amino acid and nitrogen metabolisms after treatment with (A) ethambutol, (B) isoniazid, (C) kanamycin and (D) streptomycin. All the significantly more abundant metabolites are coloured in red, while the less abundant metabolites in green (when compared to the control *M. smegmatis* samples). Identified hits with no significant changes are in orange. Corresponding names for each metabolite and pathway are also annotated.

**FIGURE S2** *Mycobacterium smegmatis* metabolic networks affected by compound 1. Compound 1 significantly affects amino acid and nitrogen (see text, Figure 2A) and, in addition, (A) pyrimidine and purine and (B) folate-dependent one-carbon metabolisms. More metabolites are coloured in red, while the less abundant metabolites are coloured in green (when compared to the control *M. smegmatis* samples). Identified hits with no significant changes are in orange. Corresponding names for each metabolite and pathway are also annotated.

**TABLE S1** Identification (as KEGG code) of metabolites found by positive ionization mode after compound 1 treatment.

**TABLE S2** Identification (as KEGG code) of metabolites found by negative ionization mode after compound 1 treatment.

**TABLE S3** Ranked enriched pathways with total number of hits found by positive ionization mode after treatment with compound 1, significant hits (*p* < 0.001), their EASE (Expression Analysis Systematic Explorer) score (Hosack et al., 2003) their raw *p*-values (Fisher’s Exact Test, FET), and the *p*-values using a Gamma distribution (all scores calculated based on the hits at *p* < 0.001).

**TABLE S4** Ranked enriched pathways with total number of hits by negative ionization mode after treatment with compound 1, significant hits (*p* < 0.001), their EASE (Expression Analysis Systematic Explorer) score (Hosack et al., 2003) their raw *p*-values (Fisher’s Exact Test, FET), and the *p*-values using a Gamma distribution (all scores calculated based on the hits at *p* < 0.001).
REFERENCES


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Crusco, Baptista, Bhowmick, Beckmann, Mur, Westwell and Hoffmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.